We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
OBI Pharma, Inc., a Taiwan, China biopharma company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for....
OBI Pharma, Inc., a Taiwan, China biopharma company, has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for OBI-888 for the treatment of Pancreatic Cancer